Preclinical studies have confirmed that the antitumor function of CD8+ T cells in melanoma is enhanced by the combined action of fatty acid metabolism and anti-PD-1 antibodies; immunotherapy-induced IFN-γ production suppresses solute carrier family 7 member 11 (SLC7A11) expression, enhances lipid oxidation, and promotes ferroptosis, thereby improving tumor control (20, 38). This evidence concerns the gene SLC7A11 and melanoma.